GoAI
Get started
Jiangxi Rimag Group Co., Ltd. logo

Jiangxi Rimag Group Co., Ltd.

2522.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$4.70

+HK$0.17 · +3.75%

Aug 24, 4:08 PM HKT

2522.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Operating across China, Jiangxi Rimag Group Co., Ltd. specializes in providing medical imaging services. The company delivers a comprehensive suite of diagnostic imaging procedures, including MRI, CT, PET scans, X-rays, ultrasounds, and mammography, serving both patients and other healthcare sector clients. It also offers sophisticated imaging solution services. Additionally, Rimag Cloud provides various digital offerings such as cloud-based storage and film modules, a cloud radiology information system (RIS), a cloud Picture Archive and Communication System (PACS), alongside modules for AI integration and operational management within imaging platforms. The firm also oversees and manages a medical imaging platform that hosts a diverse range of imaging-related services. Supporting its activities is a dedicated research and development center, and it further engages in the distribution of medical equipment and related consumables. Established in 2014, the company maintains its primary office in Beijing, China.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Zhaoyang Chen
Listed since
Jun 7, 2024
Employees
1,406

Market position

Day range

Current HK$4.70

52-week range

Current HK$4.70

Open
HK$4.55
Previous close
HK$4.53
Volume
228K
0.23× average
Average volume
1.01M
Average daily volume
Market cap
1.75B HKD
Beta
-0.73
Market reference 1
50-day average
HK$4.9394
-4.85% below average
200-day average
HK$7.6138
-38.27% below average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends46%7%-32%-71%Gross margin, FY2021: 29.59%Gross margin, FY2022: 30.21%Gross margin, FY2023: 35.80%Gross margin, FY2024: 36.46%Gross margin, FY2025: 33.81%Operating margin, FY2021: -50.31%Operating margin, FY2022: 4.97%Operating margin, FY2023: 7.78%Operating margin, FY2024: -3.56%Operating margin, FY2025: 5.70%Net margin, FY2021: -60.93%Net margin, FY2022: 0.05%Net margin, FY2023: 4.78%Net margin, FY2024: -6.04%Net margin, FY2025: 0.43%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 29.59%. Gross margin FY2022 30.21%. Gross margin FY2023 35.80%. Gross margin FY2024 36.46%. Gross margin FY2025 33.81%. Operating margin FY2021 -50.31%. Operating margin FY2022 4.97%. Operating margin FY2023 7.78%. Operating margin FY2024 -3.56%. Operating margin FY2025 5.70%. Net margin FY2021 -60.93%. Net margin FY2022 0.05%. Net margin FY2023 4.78%. Net margin FY2024 -6.04%. Net margin FY2025 0.43%.

Income trends

Revenue

873.12M HKD+14.79%

Operating income

49.79M HKD+76.9M HKD

Net income

3.75M HKD+49.67M HKD
Income trends across reported periods1.06B HKD542.02M HKD26.16M HKD−489.7M HKDRevenue, FY2021: 592.01M HKDRevenue, FY2022: 784.44M HKDRevenue, FY2023: 928.91M HKDRevenue, FY2024: 760.59M HKDRevenue, FY2025: 873.12M HKDOperating income, FY2021: −297.86M HKDOperating income, FY2022: 38.95M HKDOperating income, FY2023: 72.24M HKDOperating income, FY2024: −27.11M HKDOperating income, FY2025: 49.79M HKDNet income, FY2021: −360.73M HKDNet income, FY2022: 364K HKDNet income, FY2023: 44.42M HKDNet income, FY2024: −45.92M HKDNet income, FY2025: 3.75M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 592.01M HKD. Revenue FY2022 784.44M HKD. Revenue FY2023 928.91M HKD. Revenue FY2024 760.59M HKD. Revenue FY2025 873.12M HKD. Operating income FY2021 −297.86M HKD. Operating income FY2022 38.95M HKD. Operating income FY2023 72.24M HKD. Operating income FY2024 −27.11M HKD. Operating income FY2025 49.79M HKD. Net income FY2021 −360.73M HKD. Net income FY2022 364K HKD. Net income FY2023 44.42M HKD. Net income FY2024 −45.92M HKD. Net income FY2025 3.75M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue873.12M HKD760.59M HKD928.91M HKD784.44M HKD592.01M HKD
Cost of goods sold577.88M HKD483.26M HKD596.32M HKD547.49M HKD416.83M HKD
Gross profit295.24M HKD277.33M HKD332.6M HKD236.95M HKD175.19M HKD
Research and development15.71M HKD11.54M HKD12.84M HKD11.48M HKD11.87M HKD
Selling, general, and administrative235.6M HKD290.06M HKD96.92M HKD70.44M HKD72.57M HKD
Operating expenses245.45M HKD304.44M HKD260.35M HKD198M HKD473.05M HKD
Interest income9.4M HKD6.75M HKD6.04M HKD6.88M HKD2.93M HKD
Interest expense28.66M HKD25.27M HKD24.79M HKD37.34M HKD62.17M HKD
Depreciation and amortization199.01M HKD195.36M HKD188.03M HKD169.58M HKD153.05M HKD
Operating income49.79M HKD−27.11M HKD72.24M HKD38.95M HKD−297.86M HKD
Net income3.75M HKD−45.92M HKD44.42M HKD364K HKD−360.73M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.04

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.09-0-0.1-0.19Q3 '24Q1 '25Q3 '25Q1 '26
Q3 2024, reported Aug 27, 2024: actual 0.012, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual -0.149, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 18, 2025: actual 0.05, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual -0.039, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates532.26M471.02M409.78M348.54MQ3 '24No estimateQ1 '25No estimateQ3 '25No estimateQ1 '26No estimateQ3 '26Estimate
Q3 2024, reported Aug 27, 2024: actual 444.51M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 369.01M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 18, 2025: actual 511.79M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual 451.75M HKD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 25, 2026: actual —, estimate 496.13M HKD, surprise —, Comparison unavailable.

2522.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 2522.HK

research.disclaimer